| Stereochemistry | UNKNOWN |
| Molecular Formula | C21H23FN2O3S |
| Molecular Weight | 402.482 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[O-][S+](CCN1CCC(CC2=CC=C(F)C=C2)CC1)C3=CC4=C(NC(=O)O4)C=C3
InChI
InChIKey=FCBQJNCAKZSIAH-UHFFFAOYSA-N
InChI=1S/C21H23FN2O3S/c22-17-3-1-15(2-4-17)13-16-7-9-24(10-8-16)11-12-28(26)18-5-6-19-20(14-18)27-21(25)23-19/h1-6,14,16H,7-13H2,(H,23,25)
| Molecular Formula | C21H23FN2O3S |
| Molecular Weight | 402.482 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Besonprodil (also known as CI-1041), an NR2B subunit specific NMDA receptor antagonist, has been developed for the treatment of certain inflammatory and neuropathic pain, however, these studies were discontinued. Besides, besonprodil was investigated as a supplemental medication for Parkinson's disease. Experiments on animals have shown that this drug could be effective in counteracting the dyskinesia associated with long-term treatment with levodopa and related drugs.